MAIA reports 90.5% disease control in heavily pretreated lung cancer cohort
The Phase 2 THIO-101 Part C update showed disease control in 19 of 21 evaluable third-line NSCLC patients, but the data are early, uncontrolled, and drawn from a small subgroup.
Executive Summary
- MAIA Biotechnology reported that its Phase 2 combination of ateganosine and cemiplimab produced disease control in the large majority of evaluable patients in a third-line lung cancer expansion cohort, extending a pattern the company has described in earlier parts of the same trial.
- The patients analyzed had already failed checkpoint immunotherapy, platinum chemotherapy, and docetaxel, a heavily pretreated group where current chemotherapy options control disease at a lower rate.
- The finding rests on a small, open-label subgroup with no concurrent comparator arm, so it is an early efficacy signal rather than a controlled test of benefit.
- The trial's primary completion date has shifted four times since 2024, now extending to September 2027, and its status has flipped between recruiting and active-not-recruiting twice, though enrollment itself has held steady at its 227-patient target.
What was reported
MAIA Biotechnology said its Phase 2 THIO-101 trial delivered a 90.5% disease control rate, 19 of 21 patients, in the efficacy-evaluable population of Part C, an expansion cohort testing ateganosine followed by cemiplimab in third-line advanced NSCLC. The company said the figure is consistent with an 88% disease control rate it previously reported in Parts A and B of the same trial. Chief Executive Officer Vlad Vitoc said the Part C population was more heavily pretreated than earlier cohorts, with all patients having received prior docetaxel in addition to demonstrated resistance to both immunotherapy and other chemotherapies. MAIA said the combination has shown an acceptable safety profile to date in this pretreated population. MAIAMAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung ...Jul 8, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial tests
THIO-101 is registered as a multicenter, open-label Phase 2 study evaluating ateganosine (also called THIO or 6-thio-2'-deoxyguanosine), a modified nucleotide that targets telomeres, administered ahead of the PD-1 inhibitor cemiplimab. The trial carries ten registered primary endpoints spanning overall response rate, disease control rate, and safety and tolerability measures, evaluated in patients whose disease had secondary resistance to prior checkpoint inhibitor therapy. It is not designated a registrational study. No formal statistical testing or p-value accompanied the disclosed disease control figure, and the primary response-rate endpoints were not reported numerically in this update. NCT05208944THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944
Reading the number
The 90.5% figure applies to a 21-patient efficacy-evaluable subgroup within a trial targeting 227 total enrolled patients, and it carries no concurrent control arm for direct comparison. MAIA's press release contrasted the figure against an approximate 25% to 35% disease control rate for current chemotherapy in this setting, a benchmark drawn from the company's own materials rather than a head-to-head trial arm. A disease control rate in a subgroup of this size, evaluated without a comparator arm and using an open-label design, is an early efficacy signal rather than a decision-grade result. NCT05208944+1THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung ...Jul 8, 2026
Trial timeline
The trial's primary completion date has moved four times on the registry since late 2024: from June 2024 to August 2025, then to December 2025, then to June 2026, and now to September 2027. Its recruitment status has also toggled twice, from active-not-recruiting back to recruiting in June 2025, and back to active-not-recruiting in May 2026, as the sponsor completed enrollment. Enrollment itself held flat at its 227-patient target through this period, within the routine range for a Phase 2 program of this size. MAIA has said it holds Fast Track designation for ateganosine in NSCLC and has referenced a potential path to accelerated approval, though that regulatory outcome remains aspirational and unconfirmed against the agency's own record. NCT05208944THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944
Where it sits competitively
Telomere-targeting therapy is sparsely represented in NSCLC: broader searches of the target-by-indication class turn up ateganosine as the only Phase 2 asset of this type, while most named competitors in NSCLC pursue different mechanisms altogether. Given that no validated telomere-targeting mechanism exists in this indication, an effect that persists as this cohort matures and extends across the full 227-patient enrollment would be the result that distinguishes this signal from a favorable early subgroup.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.